R Squared Ltd Invests $26,000 in Guardant Health, Inc. (NASDAQ:GH)

R Squared Ltd bought a new position in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 860 shares of the company’s stock, valued at approximately $26,000.

Several other hedge funds also recently made changes to their positions in GH. JNBA Financial Advisors acquired a new stake in shares of Guardant Health during the third quarter worth $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Guardant Health during the third quarter worth $34,000. Nisa Investment Advisors LLC raised its position in shares of Guardant Health by 168.1% during the third quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock worth $79,000 after purchasing an additional 2,153 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Guardant Health by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after purchasing an additional 796 shares during the period. Finally, KBC Group NV raised its position in shares of Guardant Health by 63.6% during the fourth quarter. KBC Group NV now owns 5,658 shares of the company’s stock worth $173,000 after purchasing an additional 2,200 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at $228,675.20. This represents a 27.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,548 shares of company stock worth $179,782. 5.50% of the stock is owned by corporate insiders.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $47.17 on Wednesday. The company has a market capitalization of $5.83 billion, a P/E ratio of -11.12 and a beta of 1.32. The business’s 50-day moving average price is $37.47 and its two-hundred day moving average price is $30.36. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The company had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business’s revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.73) EPS. On average, equities analysts anticipate that Guardant Health, Inc. will post -3.43 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on GH shares. JPMorgan Chase & Co. boosted their target price on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. The Goldman Sachs Group upped their price target on Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Sanford C. Bernstein dropped their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Barclays started coverage on Guardant Health in a research report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target on the stock. Finally, Leerink Partners dropped their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Sixteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health presently has an average rating of “Buy” and a consensus target price of $42.63.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.